section name header

General Information

Class Name(s):

Pronunciation:

Brand Name(s):

IMPORTANT WARNING:

Tisotumab vedotin-tftv can cause changes to the cornea (clear tissue that covers the front of the eye) and conjunctiva (a membrane that lines the inside of eyes) that can lead to vision loss. Tell your doctor if you have or have ever had vision or eye problems. If you experience any of the following symptoms, call your doctor immediately: blurred vision, loss of vision, eye pain or redness, or other visual changes.

Your doctor will order an eye exam before starting your treatment and before receiving each dose of tisotumab vedotin-tftv. Keep all appointments with your doctor and your eye doctor.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with tisotumab vedotin-tftvand each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Talk to your doctor about the risks of receiving tisotumab vedotin-tftv injection.

Use

WHY is this medicine prescribed?

Tisotumab vedotin-tftv injection is used to treat cervical cancer (cancer that begins in the opening of the uterus [womb]) that has not improved or has come back after treatment with other medications or has spread to other parts of the body. Tisotumab vedotin-tftv is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.

HOW should this medicine be used?

Tisotumab vedotin-tftv injection comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually injected on day 1 of a 21-day cycle. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience.

Your doctor will prescribe 3 different eye drops for you to use during your treatment with tisotumab vedotin-tftv injection to reduce the risk of eye problems. You should bring the eye drops with you to your appointments for each treatment. Your doctor will tell you how and when to use the eye drops. Use these eye drops exactly as directed. While you are receiving tisotumab vedotin-tftv injection, your doctor or nurse will place a cold pack over your eyes.

Your doctor may delay or stop your treatment with tisotumab vedotin-ejfv injection, or treat you with additional medications, depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.

Are there OTHER USES for this medication?

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Special

What SPECIAL PRECAUTIONS should I follow?

Before receiving tisotumab vedotin-tftv injection,

What SPECIAL DIETARY instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

Side Effects

What SIDE EFFECTS can this medicine cause?

Tisotumab vedotin-tftv may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:

Tisotumab vedotin-tftv may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Overdose

What should I do in case of OVERDOSE?

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at http://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Miscellaneous

What OTHER INFORMATION should I know?

Keep a written list of all of the prescription and nonprescription (over-the-counter) medicines, vitamins, minerals, and dietary supplements you are taking. Bring this list with you each time you visit a doctor or if you are admitted to the hospital. You should carry the list with you in case of emergencies.

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS® Patient Medication Information Copyright, 2025. The American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.

Selected Revisions: April 20, 2024.